Video
Dr. Tagawa on the growing role of radiopharmaceuticals in prostate cancer
Author(s):
“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.
Video Player is loading.
In this video, Scott T. Tagawa, MD, MS, FACP, discusses ongoing and upcoming innovation in the radiopharmaceutical space for treatment of prostate cancer, as well as considerations for physicians who are administering these therapies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
Related Videos
Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
PSMA PET and treatment intensification in mHSPC
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
Amar Kishan, MD, on implications of MIRAGE trial data
Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
Amar Kishan, MD, outlines the rationale for the MIRAGE trial
Michael Cookson, MD, on potential future applications of PSMA-PET
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
Michael Cookson, MD, on challenges with PSMA-PET imaging
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
Related Content
